The EMPULSE trial showed the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure. touchCARDIO speaks with Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO) to discuss his presentation on the EMPULSE trial and the impact of SGLT-2 inhibitors and where they sit in the future treatment paradigm for heart failure.
Questions:
- What has been the impact of SGLT-2 inhibitors on the treatment of heart failure, and what questions remain unanswered? (00:13)
- What were the aims, design, and inclusion criteria of the EMPULSE trial? (03:03)
- What were the efficacy and safety findings of the study? (04:27)
- What is the clinical significance of these findings? (07:17)
- What does the future hold for SGLT-2 inhibitors in the treatment of heart failure? (08:21)
Disclosures: Mikhail Kosiborod is a consultant for Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
